Spotlight On... Zoetis offloads three manufacturing plants to Huvepharma for $40M; Novartis India completes animal health sale to Lilly; Jaguar launches pivotal trial of lead dog drug; UC Davis scores federal animal health grant; and more...

Animal health giant ($ZTS), which has been rolling out a major cost-cutting plan over the past year, has made its first major move toward drastically reducing its manufacturing overhead. The company disclosed on December 22 that it has sold two factories in North Carolina and Colorado to Huvepharma, based in Sofia, Bulgaria. Huvepharma will also take over the lease at a facility in Arkansas, and it will acquire the products that are primarily produced at the three plants. The deal, valued at $40 million, will close in the first quarter of 2016. It's all part of Zoetis' strategy to exit a total of 10 manufacturing facilities and eliminate 2,500 jobs and 5,000 underperforming SKUs. A spokeswoman for the company declined to say how many employees would be affected by the Huvepharma transaction. Read more at FiercePharmaManufacturing.

> Novartis ($NVS) India completed the sale of its assets to Elanco India, an affiliate of Eli Lilly ($LLY). Article

> Jaguar Animal Health ($JAGX) announced it has launched a pivotal clinical trial of Canalevia for the treatment of acute diarrhea in dogs. Release

> The California Animal Health and Food Safety Laboratory System, which is based at the University of California, Davis, received a $1.89 million, 5-year grant from the federal Food Emergency Response Network, which it will use to expand its toxicology services. More

> A team of researchers from the University of Tasmania in Australia and the University of Cambridge in the U.K. announced they have identified a second transmissible form of cancer in Tasmanian devils. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…